IP Library Granted Patent US 8,618,277
Granted Patent B2
US 8,618,277 · App. 13/480,655 · Granted Dec 31, 2013

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,618,277
App. No.
13/480,655
Granted
Dec 31, 2013
Kind
B2
Abstract

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.

Claims (8)

1. A short interfering RNA (siRNA) molecule having a sense strand and an antisense strand that mediates RNA interference against a Hepatitis B Virus target RNA, wherein:

(a) each strand is between 18 and 24 nucleotides in length;

(b) the sense strand comprises 10 or more 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, or universal base modified nucleotides;

(c) the antisense strand comprises 10 or more 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, or universal base modified nucleotides; and

(d) 10 or more pyrimidine nucleotides of the sense and/or antisense strand are 2′-deoxy, 2′-O-methyl or 2′-deoxy-2′-fluoro nucleotides.

2. The siRNA molecule of claim 1 , wherein the sense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 phosphorothioate internucleotide linkages.

3. The siRNA molecule of claim 1 , wherein the antisense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 phosphorothioate internucleotide linkages.

4. A composition comprising the siRNA molecule of claim 1 and a pharmaceutically acceptable carrier or diluent.

Assignments (3)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2014
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 032726/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2013
From: MCSWIGGEN, JAMES; BEIGELMAN, LEONID
To: MERCK SHARP & DOHME CORP.
Reel/Frame 031458/0700 →